# BRTX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BRTX) · [Earnings tab](https://www.lopjlb.com/stock/BRTX?tab=earnings)

Updated: 2026-09-01T07:38:30

Quarters analyzed: 7

## Cross-quarter narrative

Across seven earnings CallCards, BioRestorative’s story shifts from early-stage trial setup and partnership building toward tangible clinical readouts and expanding commercial traction. Early calls (Q1‑Q2 2024) emphasized enrollment logistics, FDA protocol amendment, and the Cartessa cosmeceutical deal as primary cash sources. By Q3 2024 the company disclosed encouraging 26‑week Phase 2 data for BRTX‑100, confirming enrollment on track and hinting at an interim analysis. The following quarters highlighted regulatory momentum—Fast‑Track designation, IND clearance for a cervical trial, and ongoing FDA interactions—while cash fell from $16.4 M to $9.1 M, prompting a $1.1 M financing in Q3 2025. ThermoStem evolved from pre‑clinical work and licensing talks to IP milestones, including a Japanese patent allowance. Revenue from the Cartessa partnership grew, culminating in $11.8 M royalty income in Q3 2025. Throughout, enrollment risk, regulatory uncertainty, and financial runway remained recurring concerns, though manufacturing and cost‑escalation worries faded. Overall, the narrative moves from foundational risk management to emerging data, regulatory approvals, and expanding revenue streams, while cash constraints and licensing outcomes remain pivotal.

## Latest CallCard · Q3

BioRestorative reported Q3 2025 royalty revenue of $11.8M, a $3M net loss, >75% enrollment in the BRTX-100 Phase II trial, biocosmeceuticals expansion and a recent $1.1M financing bolstering its balance sheet.

**Guidance:** vague — Management spoke positively but gave no specific revenue or earnings guidance.

**Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3

Management highlighted clinical enrollment progress, Fast Track status, upcoming Type B meeting and commercial expansion, conveying optimism.

### Demand visibility

Increasing demand for biocosmeceuticals and BRTX-100 data

Management cited a $63B biocosmeceutical market, new commercial head and accelerating Phase II enrollment as drivers of future demand.

### Margins / costs

Focus on cost‑efficient manufacturing and commercial scaling

Rebuilt supply chain and in‑house formulation aim to capture margin, while financing supports efficient cash use.

### Capital allocation

Recent financing strengthens balance sheet

Closed a fully‑subscribed ~$1.1M financing post‑quarter; cash, cash equivalents and marketable securities now $4.5M with no debt.

### Milestones

- **BRTX-100 Phase II enrollment** [on_track]: More than three‑quarters enrolled with >10 patients in late‑stage screening.
- **Fast Track designation for BRTX-100** [delivered]: Granted in February, enabling Type B meeting discussions.
- **Type B FDA meeting** [at_risk]: Expected December/January; outcome uncertain.
- **ThermoStem Japanese patent allowance** [delivered]: Notice of allowance issued, broadening IP protection.
- **Appointment of Crystal Romano** [new]: Global Head of Commercial Operations to drive biocosmeceutical revenue.
- **Post‑quarter financing** [delivered]: Fully‑subscribed ~$1.1M raise bolstering cash runway.
- **ThermoStem licensing discussions** [at_risk]: Ongoing talks with a commercial‑stage regenerative company, no interim update.

### Fears / risks

- **Regulatory**: Uncertainty around FDA Type B meeting outcome could delay BLA pathway.
- **Financial**: Limited cash runway despite financing may require additional capital.
- **Clinical**: Risk that Phase II enrollment may not complete as projected.
- **Market**: Biocosmeceutical revenue depends on successful distribution expansion.
- **Licensing**: ThermoStem license agreement remains uncertain.
- **Safety**: No material adverse events yet, but long‑term safety profile unknown.
- **Competition**: Few biotech players in biocosmeuticals, but market is large and competitive.
- **Operational**: Potential delays in cervical trial due to resource constraints.

### Key quotes

> “Third-quarter 2025 revenues were $11,800 and consisted entirely of royalty revenue.”

> “In February, we announced that the BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA.”

> “We believe that the strength of our expanding intellectual property portfolio further enhances the value of that platform.”

> “On the numerical side, I will say we are more than three-quarters enrolled. We have more than 10 patients in late-stage screening, which could come in for harvest within the next couple of weeks.” — Lance Alstodt

> “We are going to keep the data blinded because we have a strategy as it relates to communication with the FDA under our Fast Track designation, looking to accelerate the BLA process.”

## Quarter one-liners

- **2025 Q3:** BioRestorative reported Q3 2025 royalty revenue of $11.8M, a $3M net loss, >75% enrollment in the BRTX-100 Phase II trial, biocosmeceuticals expansion and a recent $1.1M financing bolstering its balance sheet.
- **2025 Q2:** —
- **2025 Q1:** BRTX reported Q1 revenue decline, highlighted positive blinded trends in its Phase II BRTX-100 trial, secured Fast Track and IND clearance, noted accelerating enrollment, and ended with $9.1M cash and no debt.
- **2024 Q4:** BRTX 2024: revenue
- **2024 Q3:** BRTX reported encouraging preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease: 70% of first 10 patients showed >30% improvement in pain and function at 26 weeks, strong safety, enrollment on track to complete by year-end, $13.1M cash no debt, potential interim analysis early 2025.
- **2024 Q2:** BRTX Q2: Revenue up 154% sequentially to $89k from Cartessa deal; Phase 2 BRTX-100 enrollment on track for year-end; FDA cleared protocol amendment; ThermoStem advancing with exosome candidate and licensing talks; cash $14.7M, no debt.
- **2024 Q1:** BioRestorative reported progress on its BRTX-100 Phase 2 trial with enrollment on track for end‑2024, announced FDA protocol amendment, advanced a new exosome obesity program, and highlighted a transformative Cartessa partnership while holding $16.4 M cash.

## Theme arcs

- **Clinical trial enrollment** (improving): Enrollment accelerated, >75% of target reached by Q3 2025
- **Regulatory milestones** (improving): Fast‑Track, IND clearance, and FDA meetings progressed
- **Financial position** (deteriorating): Cash declined from $16.4 M to $9.1 M before Q3 2025 financing
- **Cartessa partnership** (stable): Delivered early revenue and ongoing royalty stream
- **ThermoStem program** (new): Moved from pre‑clinical to IP filings and licensing talks
- **Data readouts** (improving): Preliminary 26‑week data and positive blinded trends reported
- **Biocosmeceutical market demand** (improving): Royalty revenue rose to $11.8 M in Q3 2025

## Fear persistence

- **Enrollment risk** [recurring]: Limited sites and strict criteria cited in multiple quarters
- **Regulatory risk** [recurring]: Uncertainty around FDA pathways, interim analysis, and Type B meeting
- **Financial risk** [recurring]: Cash runway concerns noted from Q1 2024 through Q3 2025
- **Licensing risk** [recurring]: ThermoStem licensing outcomes remain uncertain
- **Data maturity/placebo effect** [recurring]: Early data based on small cohorts, risk of confounding effects
- **Manufacturing risk** [resolved]: Scaling concerns raised in Q1 2024 but not mentioned later
- **Cost escalation risk** [resolved]: G&A cost rise noted in Q2 2024, absent in later calls

## Guidance path

2024 Q1:maintained → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/BRTX`